MCID: MYL006
MIFTS: 69

Myeloid Leukemia

Categories: Rare diseases, Cancer diseases, Blood diseases, Genetic diseases, Immune diseases

Aliases & Classifications for Myeloid Leukemia

MalaCards integrated aliases for Myeloid Leukemia:

Name: Myeloid Leukemia 12 49 28 51 14 69
Myeloid Granulocytic Leukemia 12
Non-Lymphocytic Leukemia 12
Leukemia Myelogenous 12
Leukemia, Myeloid 72

Classifications:



Summaries for Myeloid Leukemia

Disease Ontology : 12 A leukemia that is located in myeloid tissue.

MalaCards based summary : Myeloid Leukemia, also known as myeloid granulocytic leukemia, is related to core binding factor acute myeloid leukemia and acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22). An important gene associated with Myeloid Leukemia is RUNX1 (Runt Related Transcription Factor 1), and among its related pathways/superpathways are Pathways in cancer and NF-kappaB Signaling. The drugs Bosulif and Gleevec have been mentioned in the context of this disorder. Affiliated tissues include myeloid tissue, myeloid and bone, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Wikipedia : 72 Myeloid leukemia is a type of leukemia affecting myeloid... more...

Related Diseases for Myeloid Leukemia

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Acute Myeloid Leukemia with T(9;11)(p22;q23) Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 517)
# Related Disease Score Top Affiliating Genes
1 core binding factor acute myeloid leukemia 34.4 CBFB FLT3 KIT RUNX1
2 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 34.0 CBFB ETV6 FLT3 KIT MYH11 RUNX1
3 philadelphia-negative chronic myeloid leukemia 33.9 ABL1 BCR
4 acute myeloid leukemia with t(8;21)(q22;q22) translocation 33.7 FLT3 KIT RUNX1 RUNX1T1
5 acute myeloblastic leukemia with maturation 33.2 FLT3 KIT
6 leukemia, chronic myeloid 33.1 ABL1 BCR ETV6 FLT3 GATA2 HOXA9
7 myeloproliferative neoplasm 32.6 ABL1 BCR ETV6 PTPN11
8 leukemia 32.4 ABL1 BCR CBFB ETV6 FLT3 KIT
9 myelodysplastic syndrome 32.1 ABL1 ETV6 FLT3 GATA2 HOXA9 KIT
10 leukemia, acute myeloid 31.8 ABL1 BCR CBFA2T2 CBFB ETV6 FLT3
11 chronic myelomonocytic leukemia 31.1 ETV6 FLT3 KIT RUNX1
12 lymphoblastic leukemia 31.1 ABL1 BCR ETV6 FLT3 RUNX1
13 acute leukemia 31.0 ETV6 FLT3 KIT RUNX1
14 lymphoid leukemia 30.6 BCR ETV6 RUNX1 RUNX1T1
15 mn1 30.6 ETV6 FLT3
16 acute lymphocytic leukemia 30.5 BCR ETV6 MCL1 RUNX1
17 aleukemic leukemia cutis 30.3 FLT3 MYH11 RUNX1
18 8p11 myeloproliferative syndrome 30.1 BCR FLT3 KIT RUNX1
19 childhood leukemia 29.9 ABL1 ETV6 PTPN11 RUNX1
20 platelet disorder, familial, with associated myeloid malignancy 29.9 ETV6 RUNX1
21 precursor t-cell acute lymphoblastic leukemia 29.9 ABL1 BCR ETV6 FLT3 NUP98
22 leukemia, acute lymphoblastic 29.8 ABL1 BCR ETV6 FLT3 GATA2 RUNX1
23 hematologic cancer 29.1 ABL1 BCR ETV6 FLT3 GATA2 KIT
24 atypical chronic myeloid leukemia 12.5
25 cytogenetically normal acute myeloid leukemia 12.5
26 familial acute myeloid leukemia with mutated cebpa 12.3
27 acute myeloid leukemia with recurrent genetic anomaly 12.2
28 unclassified acute myeloid leukemia 12.2
29 therapy related acute myeloid leukemia and myelodysplastic syndrome 12.1
30 acute myeloid leukemia with minimal differentiation 12.1
31 acute myeloid leukemia with t(9;11)(p22;q23) 12.1
32 acute myeloid leukemia with t(8;16)(p11;p13) translocation 12.1
33 acute myeloid leukemia with t(6;9)(p23;q34) 12.1
34 acute promyelocytic leukemia 12.1
35 cebpa-associated familial acute myeloid leukemia 12.1
36 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) 12.0
37 acute myeloid leukemia and myelodysplastic syndromes related to radiation 12.0
38 megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13) 12.0
39 acute myeloid leukemia with npm1 somatic mutations 12.0
40 acute myeloid leukemia with 11q23 abnormalities 12.0
41 acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent 12.0
42 acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor 12.0
43 megakaryocytic leukemia 11.9
44 aml with myelodysplasia-related features 11.8
45 mast-cell leukemia 11.5
46 myeloid sarcoma 11.5
47 pdgfrb-associated chronic eosinophilic leukemia 11.5
48 essential thrombocythemia 11.5
49 leukostasis 11.3
50 juvenile myelomonocytic leukemia 11.3

Graphical network of the top 20 diseases related to Myeloid Leukemia:



Diseases related to Myeloid Leukemia

Symptoms & Phenotypes for Myeloid Leukemia

GenomeRNAi Phenotypes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.63 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.63 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.63 ABL1 FLT3 KIT
4 Increased shRNA abundance GR00327-A 9.35 ERG FLT3 MCL1 MYH11 PTPN11
5 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 9.17 CBFA2T2 GATA2 MCL1 MLF1 NUP98 RUNX1

MGI Mouse Phenotypes related to Myeloid Leukemia:

43 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.41 ETV6 HOXA9 KIT FLT3 GATA2 MYH11
2 cellular MP:0005384 10.4 GATA2 ETV6 KIT FLT3 MYH11 MCL1
3 hematopoietic system MP:0005397 10.34 GATA2 ETV6 HOXA9 KIT FLT3 MCL1
4 cardiovascular system MP:0005385 10.31 GATA2 ETV6 KIT MYH11 MECOM PTPN11
5 endocrine/exocrine gland MP:0005379 10.3 GATA2 ETV6 HOXA9 KIT FLT3 MCL1
6 immune system MP:0005387 10.3 ETV6 HOXA9 KIT FLT3 MCL1 NUP98
7 embryo MP:0005380 10.28 GATA2 ETV6 KIT MCL1 NUP98 MECOM
8 mortality/aging MP:0010768 10.27 GATA2 ETV6 KIT FLT3 MYH11 MCL1
9 homeostasis/metabolism MP:0005376 10.26 ERG GATA2 ETV6 FLT3 KIT MYH11
10 digestive/alimentary MP:0005381 10.2 ETV6 KIT MYH11 PTPN11 RUNX1T1 CBFA2T2
11 integument MP:0010771 10.13 ETV6 HOXA9 KIT MYH11 MCL1 MECOM
12 normal MP:0002873 10.03 ETV6 KIT GATA2 MCL1 PTPN11 MECOM
13 liver/biliary system MP:0005370 10.01 GATA2 KIT MECOM PTPN11 RUNX1 ABL1
14 neoplasm MP:0002006 9.92 ETV6 FLT3 KIT MECOM PTPN11 RUNX1
15 reproductive system MP:0005389 9.81 ERG GATA2 HOXA9 KIT MCL1 MECOM
16 respiratory system MP:0005388 9.56 ERG KIT MYH11 MECOM PTPN11 RUNX1
17 skeleton MP:0005390 9.28 ERG HOXA9 FLT3 KIT MECOM PTPN11

Drugs & Therapeutics for Myeloid Leukemia

FDA approved drugs:

(show all 8)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Bosulif 17 45 BOSUTINIB MONOHYDRATE Pfizer September 2012
2
Gleevec 17 45 IMATINIB MESYLATE Novartis May 2001
3
Iclusig 17 45 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
4
Lynparza 17 45 OLAPARIB AstraZeneca December 2014
5
Mylotarg 17 45 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
6
Sprycel 17 45 DASATINIB Bristol-Myers Squibb June 2006
7
Synribo 17 45 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical October 2012
8
Tasigna 17 45 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007

Drugs for Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 676)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
2
Daunorubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 20830-81-3 30323
3
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
4
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
5
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
6
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
7
Amsacrine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 51264-14-3 2179
8
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
9
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 302962-49-8 3062316
10
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
11
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24356-66-9 21704 32326
12
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 51-45-6, 75614-87-8 774
13
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
14 Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
15
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
16
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1 191732-72-6 216326
17
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 110942-02-4, 85898-30-2
18
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 320-67-2 9444
19
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2353-33-5 451668
20
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
21
Nicotine Approved Phase 4 54-11-5 89594 942
22
Bupropion Approved Phase 4,Phase 2 34911-55-2, 34841-39-9 444
23
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 477468 3081921
24
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 171228-49-2 147912
25
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
26
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
27 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
28
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 2 67-97-0 10883523 5280795 6221
29
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
30
Lactitol Investigational Phase 4,Phase 2,Phase 3,Phase 1 585-86-4 3871
31
Aclarubicin Investigational Phase 4,Phase 2,Phase 1 57576-44-0 451415
32
Histamine Phosphate Phase 4,Phase 3,Phase 1,Phase 2 51-74-1 65513
33 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
34 interferons Phase 4,Phase 3,Phase 2,Phase 1
35 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 topoisomerase I inhibitors Phase 4,Phase 2,Phase 1
37 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
38 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
39 Gemtuzumab Phase 4,Phase 2,Phase 3,Phase 1
40 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
43 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
44 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
46 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
47 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
49 Hormones Phase 4,Phase 3,Phase 2,Phase 1
50 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 2934)

# Name Status NCT ID Phase Drugs
1 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
2 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
3 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
4 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
5 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
6 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
7 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
8 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
9 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
10 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
11 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
12 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
13 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
14 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
15 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
16 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
17 Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
18 Efficacy and Safety of Nilotinib in CML-CP Completed NCT03332511 Phase 4 Nilotinib
19 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
20 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients Completed NCT00180115 Phase 4 Cytarabine Dosage
21 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
22 An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
23 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Completed NCT00171899 Phase 4 imatinib mesylate
24 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
25 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Completed NCT01227577 Phase 4 Nilotinib
26 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
27 Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
28 Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care Completed NCT00161668 Phase 4 Mylotarg
29 Tasigna in Glivec-resistant or Intolerant Patients in CML Completed NCT01206088 Phase 4 nilotinib
30 Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia Completed NCT00304447 Phase 4 Mylotarg
31 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed NCT00686543 Phase 4 Posaconazole
32 A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome Completed NCT01041846 Phase 4 No intervention
33 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
34 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
35 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
36 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia Recruiting NCT02602314 Phase 4 Imatinib;Nilotinib
37 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Recruiting NCT03216070 Phase 4 Dasatinib 50 MG
38 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
39 Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
40 Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib Recruiting NCT02689440 Phase 4 Dasatinib
41 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Recruiting NCT02027064 Phase 4 Interferon-alpha
42 Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. Recruiting NCT02546674 Phase 4 Nilotinib
43 Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients Recruiting NCT02267993 Phase 4 recombinant human thrombopoietin
44 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
45 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
46 Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia Active, not recruiting NCT01819792 Phase 4
47 Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
48 Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Active, not recruiting NCT02228382 Phase 4 Bosutinib
49 A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients Active, not recruiting NCT02204722 Phase 4 600mg/day of Imatinib;400mg/day of Imatinib
50 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Active, not recruiting NCT01200355 Phase 4 micafungin;posaconazole

Search NIH Clinical Center for Myeloid Leukemia

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Myeloid Leukemia

Genetic tests related to Myeloid Leukemia:

# Genetic test Affiliating Genes
1 Myeloid Leukemia 28

Anatomical Context for Myeloid Leukemia

The Foundational Model of Anatomy Ontology organs/tissues related to Myeloid Leukemia:

18
Myeloid Tissue

MalaCards organs/tissues related to Myeloid Leukemia:

38
Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Testes, Breast

Publications for Myeloid Leukemia

Articles related to Myeloid Leukemia:

(show top 50) (show all 6043)
# Title Authors Year
1
A phase I study of CPI-613 in combination with high dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia. ( 29437791 )
2018
2
High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia. ( 29032147 )
2018
3
High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts. ( 29402726 )
2018
4
Q482H mutation of procaspase-8 in acute myeloid leukemia abolishes caspase-8-mediated apoptosis by impairing procaspase-8 dimerization. ( 29191655 )
2018
5
Acute external otitis as debut of acute myeloid leukemia - A case and review of the literature. ( 29447882 )
2018
6
Treatment of High-Risk Acute Myeloid Leukemia With Cladribine, Cytarabine, Mitoxantrone, and Granulocyte Colony-Stimulating Factor Then Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series. ( 29407318 )
2018
7
Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review. ( 29404721 )
2018
8
Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia. ( 28776669 )
2018
9
Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B cell Lymphoma and Acute Myeloid Leukemia: A Report of Two Cases. ( 29321428 )
2018
10
Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning. ( 29416633 )
2018
11
Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines. ( 29437468 )
2018
12
No Mutation Left Behind: The Impact of Reporting Recurrent Genetic Abnormalities on Outcomes of Patients with Acute Myeloid Leukemia. ( 29444505 )
2018
13
Pulmonary Langerhans cell histiocytosis, acute myeloid leukemia, and myelofibrosis in a large family and review of the literature. ( 29428448 )
2018
14
Pilot Study on Mass Spectrometry-Based Analysis of the Proteome of CD34a8_CD123a8_ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia. ( 29439554 )
2018
15
Selenite and methylseleninic acid epigenetically affects distinct gene sets in myeloid leukemia: A genome wide epigenetic analysis. ( 29438720 )
2018
16
Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia. ( 29435331 )
2018
17
Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. ( 29449224 )
2018
18
Multiple small bowel perforations due to invasive aspergillosis in a patient with acute myeloid leukemia: case report and a systematic review of the literature. ( 29357049 )
2018
19
Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy. ( 29343975 )
2018
20
Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia. ( 28960408 )
2018
21
A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia. ( 29439669 )
2018
22
A regulatory circuitry between miR-193a/miR-600 and WT1 enhances leukemogenesis in acute myeloid leukemia. ( 29452230 )
2018
23
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis. ( 29080220 )
2018
24
Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. ( 29448058 )
2018
25
Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. ( 29442179 )
2018
26
Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. ( 29330391 )
2018
27
Atypical chronic myeloid leukemia: a rare entity with management challenges. ( 29226717 )
2018
28
Evolution of cytogenetically normal acute myeloid leukemia during therapy and relapse: An exome sequencing study of 50 patients. ( 29330206 )
2018
29
HLA-Matched Sibling Vs. Unrelated Vs. Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: a Single-Center Donor Comparison. ( 29448057 )
2018
30
Prognostic significance of The Wilms' Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia. ( 29407184 )
2018
31
Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. ( 29451695 )
2018
32
Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors. ( 29438697 )
2018
33
Therapy-free remission in chronic myeloid leukemia: possible mechanism. ( 29448857 )
2018
34
Downregulated miR-217A expression predicts a poor outcome in acuteA myeloid leukemia. ( 29439315 )
2018
35
Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia. ( 29431568 )
2018
36
Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia. ( 27819671 )
2017
37
CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. ( 28031480 )
2017
38
Phase III clinical trial (RERISE study) results of Efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia. ( 28939746 )
2017
39
Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4. ( 27636548 )
2017
40
Decreased miR-144 expression as a non-invasive biomarker for acute myeloid leukemia patients. ( 29441994 )
2017
41
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. ( 28191887 )
2017
42
The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells. ( 28045930 )
2017
43
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients. ( 28407515 )
2017
44
CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia. ( 28097942 )
2017
45
MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences. ( 29180669 )
2017
46
Subcellular localization of the FLT3-ITD oncogene plays a significant role in the production of NOX- and p22(phox)-derived reactive oxygen species in acute myeloid leukemia. ( 27870947 )
2017
47
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? ( 27915304 )
2017
48
Modulation of mutant Huntingtin aggregates and toxicity by human myeloid leukemia factors. ( 27840155 )
2017
49
Advances in immunotherapy for pediatric acute myeloid leukemia. ( 28945115 )
2017
50
Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia. ( 28076884 )
2017

Variations for Myeloid Leukemia

Expression for Myeloid Leukemia

Search GEO for disease gene expression data for Myeloid Leukemia.

Pathways for Myeloid Leukemia

GO Terms for Myeloid Leukemia

Cellular components related to Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.55 ABL1 CBFA2T2 CBFB ERG ETV6 FLT3

Biological processes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 transcription by RNA polymerase II GO:0006366 9.91 CBFB ERG ETV6 GATA2 MEIS1 NUP98
2 protein autophosphorylation GO:0046777 9.84 ABL1 BCR FLT3 KIT
3 peptidyl-tyrosine phosphorylation GO:0018108 9.83 ABL1 BCR FLT3 KIT
4 regulation of hematopoietic stem cell differentiation GO:1902036 9.76 ABL1 CBFB GATA2 RUNX1
5 platelet-derived growth factor receptor signaling pathway GO:0048008 9.65 ABL1 BCR PTPN11
6 cell fate determination GO:0001709 9.63 GATA2 MCL1
7 regulation of keratinocyte differentiation GO:0045616 9.62 CBFB RUNX1
8 regulation of intracellular estrogen receptor signaling pathway GO:0033146 9.62 CBFB RUNX1
9 regulation of regulatory T cell differentiation GO:0045589 9.61 CBFB RUNX1
10 negative regulation of programmed cell death GO:0043069 9.61 KIT MECOM
11 regulation of bicellular tight junction assembly GO:2000810 9.6 CBFB RUNX1
12 regulation of myeloid cell differentiation GO:0045637 9.59 CBFB RUNX1
13 regulation of response to DNA damage stimulus GO:2001020 9.58 ABL1 MCL1
14 regulation of B cell receptor signaling pathway GO:0050855 9.58 CBFB RUNX1
15 negative regulation of myeloid cell differentiation GO:0045638 9.58 GATA2 HOXA9 MEIS1
16 Bergmann glial cell differentiation GO:0060020 9.57 ABL1 PTPN11
17 regulation of cytokine-mediated signaling pathway GO:0001959 9.56 CBFB RUNX1
18 megakaryocyte development GO:0035855 9.5 KIT MEIS1 PTPN11
19 hematopoietic stem cell proliferation GO:0071425 9.43 ETV6 MECOM RUNX1
20 hemopoiesis GO:0030097 9.35 FLT3 GATA2 KIT MEIS1 RUNX1
21 myeloid progenitor cell differentiation GO:0002318 9.33 FLT3 KIT MLF1
22 definitive hemopoiesis GO:0060216 9.02 BCR CBFB GATA2 HOXA9 MEIS1
23 regulation of transcription, DNA-templated GO:0006355 10.25 ABL1 CBFA2T2 ERG ETV6 GATA2 HOXA9
24 transcription, DNA-templated GO:0006351 10.21 CBFA2T2 ERG ETV6 GATA2 HOXA9 MECOM
25 cell differentiation GO:0030154 10.04 ERG ETV6 FLT3 GATA2 MCL1 MECOM
26 protein phosphorylation GO:0006468 10.03 ABL1 BCR ERG FLT3 KIT
27 positive regulation of transcription by RNA polymerase II GO:0045944 10.03 CBFB ERG ETV6 GATA2 HOXA9 MEIS1

Molecular functions related to Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.83 ERG ETV6 GATA2 HOXA9 MEIS1
2 DNA binding transcription factor activity GO:0003700 9.76 CBFA2T2 CBFB ERG ETV6 GATA2 MECOM
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.72 ERG ETV6 GATA2 HOXA9 MEIS1
4 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 9.71 ERG ETV6 GATA2 MEIS1
5 DNA binding GO:0003677 9.7 ABL1 CBFB ERG ETV6 GATA2 HOXA9
6 protein domain specific binding GO:0019904 9.67 ABL1 ETV6 MLF1 PTPN11
7 protein binding GO:0005515 9.62 ABL1 BCR CBFA2T2 CBFB ERG ETV6
8 protein tyrosine kinase activity GO:0004713 9.56 ABL1 BCR FLT3 KIT

Sources for Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....